Bionow Oncology & Precision Medicine Conference

Professor Tim Maughan is Professor of Oncology at the University of Liverpool and Professor Emeritus at the University of Oxford. He continues clinical practice in Gastrointestinal cancers in the Oxford region.

Tim is known for his research in colorectal cancer, mainly as a clinical trial leader. He led four UK national MRC studies (CRO6, COIN, FOCUS3 and FOCUS4) and has published extensive papers both reporting the clinical findings and translational research studies from these trials. He also led the MRC stratified medicine consortium in colorectal cancer (S:CORT) including 7 UK universities in collaborative research. This has generated a rich dataset of 2000 colorectal cancer patients including anonymised clinical data, genomic transcriptomic and methylation data all linked to digitised image of the H&E slide.

Previously Tim worked in Cardiff as an NHS oncologist where he set up the Wales Cancer Trials Network and subsequently led the development of the clinical research infrastructure across the NHS in Wales. From 2011-2021, Tim was Clinical Director of the MRC/CRUK Oxford Institute for Radiation Oncology. Tim has previously chaired the Clinical Research Committee for Cancer Research UK and the Strategy Advisory Group for NCRI.

Marian is the Chief Executive for Precision Medicine Scotland and has worked there for 3 years. She has a background in Management, Business Development and Professional Relations working in large pharmaceutical companies, including Eli Lilly and AstraZeneca. She recently (2016) gained a Masters in Stratified Medicine and Pharmacological Innovation from the University of Glasgow.

She has extensive experience of the medical marketing interface for oncology pipeline products and has been part of a large multi-disciplinary team focused on development through to successful launch of targeted treatments for cancer.

Caroline Phillips joined Redx in 2015 and held a number of senior management roles before being appointed Chief Scientific Officer in May 2024. Caroline has extensive experience in drug discovery and early clinical development, with over 25 years’ industry experience including 14 years at AstraZeneca. Caroline has been instrumental in the development of Redx’s oncology pipeline, including progressing Redx’s lead oncology asset, RXC004, a potential best-in-class, orally bioavailable porcupine inhibitor into clinical studies. Additionally, Caroline has led many of the discovery projects from early-stage target selection through pre-clinical testing and has also been fundamental in securing research collaborations and partnerships with Jazz Pharmaceuticals.

Caroline has a PhD in pharmacology form the University of Cambridge.